logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore

prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Biofil Chemicals & Pharmaceuticals Ltd

Biofil Chemicals & Pharmaceuticals

Small Cap26 EmployeesIPO 1993
Current Price
30.63
0.07 (0.23%)Updated
NSE :BIOFILCHEM
BSE :524396
Today's Range
29.6
30.63
indicator
31.56
52 Week Range
52W Low28.50
52W High57.19
30.63
indicator
Downside7.47%
Upside86.71%

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
56.57 Cr
Market Cap
Total market value of company
P/E Ratio
19.79
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
3.18
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
1.75
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
1.41%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
4.12%
ROCE
Return on Capital Employed. >15% is good
Net Margin
6.72%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-14.32%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
7.63%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
-23.80%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
1318.00%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.03
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
11.54
Book Value
Net asset value per share
Dividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
46.80%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • Very low debt-to-equity ratio (0.03) indicates strong financial stability.
  • Reported impressive 1318% quarter-on-quarter profit growth, signaling a turnaround.

Weaknesses

5 points
  • Very low ROE (3.03%) and ROCE (4.12%) indicate inefficient capital utilization.
  • Latest quarterly sales declined significantly by 23.80% to 6.43 Cr.

Opportunities

5 points
  • Capitalize on broader pharmaceutical sector growth and increasing healthcare demand.
  • Small market cap allows scope for product portfolio diversification or market expansion.

Threats

5 points
  • Faces stiff competition from larger, more profitable peers in the Pharmaceuticals sector.
  • Highly regulated pharmaceutical industry poses constant threat of new compliance requirements.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

Recent Insider Transactions

Insider NameTransaction DateFiling DateTotal SharesChangePriceAction
Niyati Shah
06 Jun 202510 Jun 20257.94 L
4.94 L
-BUY

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R435.51+₹4.88+15.94%
R333.55+₹2.92+9.54%
R232.56+₹1.93+6.29%
R131.59+₹0.96+3.15%
PIVOT30.60-0.03-0.11%
CURRENT30.63--
S125.71-₹4.92-16.05%
S227.67-₹2.96-9.65%
S328.64-₹1.99-6.51%
S429.63-₹1.00-3.25%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
0.14L
(12 Mar 2026)
-24.5% vs avg
Delivery %
58.6%
(12 Mar 2026)
-3.5% vs avg
Avg Volume (20D)
0.18L
(12 Feb - 12 Mar)
20-day average
Avg Delivery %
62.1%
(12 Feb - 12 Mar)
Trend ↓
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Vineet Laboratories Ltd
59.20 %
Highest Dividend Yield
Sun Pharmaceutical Industries Ltd
0.91 %

Peer Comparison

Company Name
LASA
Lasa Supergenerics Ltd
MANGALAM
Mangalam Drugs and Organics Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
VAISHALI
Vaishali Pharma Ltd
VINEETLAB
Vineet Laboratories Ltd

About

BIOFILCHEM

Biofil Chemicals & Pharmaceuticals Ltd

Biofil Chemicals and Pharmaceuticals Limited (Biofilchem) is an Indian company primarily engaged in the manufacturing and trading of pharmaceuticals and chemicals. Their business model encompasses two key divisions: Pharmaceuticals and Chemicals. This dual approach allows them to cater to a broader market, encompassing both the production of essential drug components and the finished pharmaceutical products themselves.

The Chemical division focuses on the production and supply of a range of basic drugs and chemical compounds. Their product portfolio includes a variety of inorganic salts crucial in pharmaceutical formulations, such as sodium chloride, potassium chloride, and sodium citrate. They also manufacture organic compounds like diethylcarbamazine citrate, used in anthelmintic medications. In addition to these, Biofilchem produces key excipients, including ferrous sulphate (in both dried and standard forms) and ferrous fumarate, which are frequently used in the manufacture of iron supplements. The company also supplies microcrystalline cellulose, a common pharmaceutical excipient for tablet formulation, and dicyclomine hydrochloride, an antispasmodic agent.

Beyond the core chemical production, Biofilchem also contributes to the packaging side of the pharmaceutical industry. They manufacture plastic drippers and caps, essential components for packaging liquid medications, providing a comprehensive supply chain solution for pharmaceutical companies. This vertical integration strategy strengthens their position within the market and potentially offers improved cost control.

Furthermore, Biofilchem offers job work services, acting as a contract manufacturer for other pharmaceutical companies. This facet of their business involves producing pharmaceutical drugs on behalf of third parties, leveraging their existing manufacturing capabilities to expand their revenue streams and diversify their client base. This service likely contributes to their overall profitability and ensures consistent utilization of their production facilities.

In summary, Biofilchem's business is multifaceted, ranging from the production of essential chemical raw materials and excipients to the manufacturing of finished pharmaceutical products and packaging components. The company's integrated approach, encompassing manufacturing, trading, and contract manufacturing, allows for a diversified and relatively resilient business model within the Indian pharmaceutical market. Established in 1985 and headquartered in Indore, India, Biofilchem has developed a strong foundation within the pharmaceutical and chemical landscape.

COMPANY FACTS - BIOFILCHEM

Registered Address

11/12 Sector E Sanwer Road

Indore

MADHYA PRADESH

IN

Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 26

IPO Date: 25/10/1993

MANAGEMENT - BIOFILCHEM

Mr. Pavan Rajput

Chief Financial Officer

Shri. Ketan Shah

Whole Time Director

Mr. Meet Shah

Additional Promoter Non-Executive Director

Mr. Satish Beohar

Additional Non-Executive Independent Director

Smt. Gayatri Padiyar

Non-Executive Independent Director

Mr. Ashok Ramawat

Non-Executive Independent Director

Investor Questions Answered

Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) Stock FAQs

Get answers to the most common questions about Biofil Chemicals & Pharmaceuticals Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) is ₹30.63. Today, the stock has gained by ₹0.07 (0.23%), trading in a range of ₹29.6 to ₹31.56. The stock opened at ₹30.06 with a trading volume of 13,938 shares.
Biofil Chemicals & Pharmaceuticals Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹56.57 crores, P/E ratio of 19.79, ROE of 1.41%, and ROCE of 4.12%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) is ₹57.19, while the 52-week low is ₹28.5. Currently trading at ₹30.63, the stock is 7.4% away from its 52-week low and 46.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Biofil Chemicals & Pharmaceuticals Ltd stock at ₹30.63 depends on multiple factors. The stock is currently trading with a P/E ratio of 19.79 and P/B ratio of N/A. Today's performance shows a gain of 0.23%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Biofil Chemicals & Pharmaceuticals Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹30.63, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Biofil Chemicals & Pharmaceuticals Ltd's key financial metrics include: P/E Ratio: 19.79, P/B Ratio: N/A, ROE: 1.41%, ROCE: 4.12%, Dividend Yield: 0.00%, EPS: ₹1.75, Book Value: ₹11.54, Debt-to-Equity: 0.03, and Current Ratio: N/A. The company's market cap stands at ₹56.57 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Biofil Chemicals & Pharmaceuticals Ltd stock opened at ₹30.06 and is currently trading at ₹30.63, showing a gain of ₹0.07 (0.23%). The intraday high is ₹31.56 and low is ₹29.6. The trading volume stands at 13,938 shares, indicating moderate market participation today.
Biofil Chemicals & Pharmaceuticals Ltd has a Price-to-Earnings (P/E) ratio of 19.79, which means investors are willing to pay ₹19.79 for every ₹1 of earnings. With an EPS of ₹1.75, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
Biofil Chemicals & Pharmaceuticals Ltd has a market capitalization of ₹56.57 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹30.63) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Biofil Chemicals & Pharmaceuticals Ltd has a book value of ₹11.54 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹30.63, which is 165.4% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Biofil Chemicals & Pharmaceuticals Ltd has a Return on Equity (ROE) of 1.41% and Return on Capital Employed (ROCE) of 4.12%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Biofil Chemicals & Pharmaceuticals Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Biofil Chemicals & Pharmaceuticals Ltd has a debt-to-equity ratio of 0.03, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Biofil Chemicals & Pharmaceuticals Ltd has an Earnings Per Share (EPS) of ₹1.75, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹30.63 and P/E ratio of 19.79, investors are paying 19.79 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Biofil Chemicals & Pharmaceuticals Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Biofil Chemicals & Pharmaceuticals Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Biofil Chemicals & Pharmaceuticals Ltd stock, consider: 1) Fundamental Analysis - Review P/E (19.79), ROE (1.41%), debt-to-equity (0.03), and growth rates. 2) Technical Analysis - Check 52-week range (₹28.50 - ₹57.19), moving averages, and chart patterns. 3) Valuation - Compare current price (₹30.63) with book value (₹11.54) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Biofil Chemicals & Pharmaceuticals Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹30.63 is 206x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Biofil Chemicals & Pharmaceuticals Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹28.50 - ₹57.19). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.03 indicates leverage. 4) Liquidity Risk - Based on trading volume of 13,938 shares. 5) Valuation Risk - P/E of 19.79 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Biofil Chemicals & Pharmaceuticals Ltd operates in the industry with key metrics: P/E ratio of 19.79, ROE of 1.41%, market cap of ₹56.57 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.03), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Biofil Chemicals & Pharmaceuticals Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹30.63, with a 52-week range of ₹28.50 to ₹57.19. Based on fundamentals like P/E (19.79), ROE (1.41%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Biofil Chemicals & Pharmaceuticals Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹30.63. 2) Fundamental Deterioration - Declining ROE (currently 1.41%), increasing debt (D/E: 0.03), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Biofil Chemicals & Pharmaceuticals Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.